Abstract

Hidradenitis suppurativa (HS) is a chronic skin disorder of unknown etiology that manifests as recurrent, painful lesions. Cutaneous dysbiosis and unresolved inflammation are hallmarks of active HS, but their origin and interplay remain unclear. Our metabolomic profiling of HS skin revealed an abnormal induction of the kynurenine pathway of tryptophan catabolism in dermal fibroblasts, correlating with the release of kynurenine pathway–inducing cytokines by inflammatory cell infiltrates. Notably, overactivation of the kynurenine pathway in lesional skin was associated with local and systemic depletion in tryptophan. Yet the skin microbiota normally degrades host tryptophan into indoles regulating tissue inflammation via engagement of the aryl hydrocarbon receptor (AHR). In HS skin lesions, we detected contextual defects in AHR activation coinciding with impaired production of bacteria-derived AHR agonists and decreased incidence of AHR ligand-producing bacteria in the resident flora. Dysregulation of tryptophan catabolism at the skin-microbiota interface thus provides a mechanism linking the immunological and microbiological features of HS lesions. In addition to revealing metabolic alterations in patients with HS, our study suggests that correcting AHR signaling would help restore immune homeostasis in HS skin.

Highlights

  • Hidradenitis suppurativa (HS), known as Verneuil’s disease and acne inversa, is an inflammatory disease of the pilosebaceous follicle, which typically starts in the second decade of life

  • Quin is a downstream product of the kynurenine (Kyn) pathway of tryptophan (Trp) catabolism culminating in NAD+ production (Figure 1E)

  • We reveal that patients with Hurley stage I HS display local and systemic alterations in Trp metabolism

Read more

Summary

Introduction

Hidradenitis suppurativa (HS), known as Verneuil’s disease and acne inversa, is an inflammatory disease of the pilosebaceous follicle, which typically starts in the second decade of life. The average prevalence of HS is 1%, with a 3-fold greater incidence in women than men [1]. In most patients (68%), HS manifests as recurrent subcutaneous nodules or abscesses (stage I lesions in Hurley’s severity classification). Some patients develop more severe forms of the disease, with fistulas (Hurley II, 28%) or multiple interconnecting lesions (Hurley III, 4%). In addition to causing intense pain, HS is commonly associated with depressive symptoms and anxiety [2]. There is no standard treatment or definitive cure for HS, but immunomodulatory drugs, antibiotics, and surgical resection can reduce symptoms [1]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.